Tesla Motors (NASDAQ:TSLA): Wedbush believes that Tesla will report essentially in-line third-quarter 2013 results with strong vehicle deliveries; the firm thinks the company could divulge several positive catalysts on the third-quarter results conference call. The analyst reiterates a $240 price target and Outperform rating on Tesla shares.
Vertex Pharmaceuticals (NASDAQ:VRTX): Bernstein downgraded Vertex to Market Perform from Outperform, as the firm does not expect the company’s HCV treatment, Vx135, to succeed, and its estimate of Vertex’s revenue from its CF treatments is 20 percent below consensus.
Merck & Co. (NYSE:MRK): BMO Capital upgraded Merck to Outperform from Market Perform following the recent pullback on the belief that shares are near a bottom; BMO says consensus estimates have come down and that a number of new data catalysts could move the shares higher. The firm has upped its price target for Merck stock to $50 from $48.
J.C. Penney & Co. (NYSE:JCP): ITG Research raised its quarterly revenue estimate for J.C. Penney to $2.81 million from $2.275 million, given that the company has experienced sales growth recently.